[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK1888761T3 - Rekombinante N-glycosylerede proteiner fra prokaryote celler - Google Patents

Rekombinante N-glycosylerede proteiner fra prokaryote celler

Info

Publication number
DK1888761T3
DK1888761T3 DK06753552.6T DK06753552T DK1888761T3 DK 1888761 T3 DK1888761 T3 DK 1888761T3 DK 06753552 T DK06753552 T DK 06753552T DK 1888761 T3 DK1888761 T3 DK 1888761T3
Authority
DK
Denmark
Prior art keywords
recombinant
proteins
prokaryotic cells
glycosylated proteins
glycosylated
Prior art date
Application number
DK06753552.6T
Other languages
English (en)
Inventor
Markus Aebi
Umesh Ahuja
Michael Kowarik
Original Assignee
Eth Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eth Zuerich filed Critical Eth Zuerich
Application granted granted Critical
Publication of DK1888761T3 publication Critical patent/DK1888761T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK06753552.6T 2005-05-11 2006-05-10 Rekombinante N-glycosylerede proteiner fra prokaryote celler DK1888761T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05010276 2005-05-11
PCT/EP2006/004397 WO2006119987A2 (en) 2005-05-11 2006-05-10 Recombinant n-glycosylated proteins from procaryotic cells

Publications (1)

Publication Number Publication Date
DK1888761T3 true DK1888761T3 (da) 2010-11-01

Family

ID=37396912

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10179208T DK2311972T3 (da) 2005-05-11 2006-05-10 Rekombinante N-glycosylerede proteiner fra prokaryotiske celler
DK06753552.6T DK1888761T3 (da) 2005-05-11 2006-05-10 Rekombinante N-glycosylerede proteiner fra prokaryote celler

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK10179208T DK2311972T3 (da) 2005-05-11 2006-05-10 Rekombinante N-glycosylerede proteiner fra prokaryotiske celler

Country Status (19)

Country Link
US (3) US8753864B2 (da)
EP (3) EP2311972B1 (da)
JP (3) JP5356807B2 (da)
KR (2) KR101408653B1 (da)
CN (2) CN101360831B (da)
AT (1) ATE483027T1 (da)
AU (1) AU2006245969B8 (da)
CA (1) CA2607595C (da)
CY (1) CY1116285T1 (da)
DE (1) DE602006017207D1 (da)
DK (2) DK2311972T3 (da)
ES (3) ES2703061T3 (da)
HK (3) HK1113588A1 (da)
HR (1) HRP20150312T1 (da)
IL (2) IL187293A (da)
PL (1) PL2311972T3 (da)
PT (2) PT1888761E (da)
SI (1) SI2311972T1 (da)
WO (1) WO2006119987A2 (da)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
ES2258214T3 (es) 2002-03-07 2006-08-16 Eidgenossische Technische Hochschule Zurich Sistema y procedimiento para la produccion de proteinas glucosiladas recombinantes en un huesped procariotico.
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP2055189A1 (en) 2003-04-09 2009-05-06 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
WO2005070138A2 (en) 2004-01-08 2005-08-04 Neose Technologies, Inc. O-linked glycosylation of peptides
CN101083907B (zh) 2004-03-03 2012-10-10 雷文斯治疗公司 用于局部诊断剂和治疗剂运输的组合物和方法
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
CA2585758C (en) 2004-10-29 2017-08-01 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
EP2514757A3 (en) 2005-01-10 2014-03-05 ratiopharm GmbH Glycopegylated granulocyte colony stimulating factor
KR20070110402A (ko) 2005-03-03 2007-11-16 레반스 테라퓨틱스 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및방법
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP1891231A4 (en) 2005-05-25 2011-06-22 Novo Nordisk As GLYCOPEGYLATED FACTOR IX
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US20080274958A1 (en) 2006-07-21 2008-11-06 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
RS52845B (en) 2007-04-03 2013-12-31 Biogenerix Ag TREATMENT PROCEDURES USING GLYCOPEGILATED G-CSF
CA2690611C (en) 2007-06-12 2015-12-08 Novo Nordisk A/S Improved process for the production of nucleotide sugars
CN107119095B (zh) 2008-01-03 2022-07-05 康乃尔研究基金会有限公司 原核生物中的糖基化蛋白表达
JP5647899B2 (ja) * 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
KR20100123730A (ko) * 2008-02-20 2010-11-24 글리코박신 아게 원핵생물 세포로부터의 ｎ-당화된 재조합 단백질로부터 제조된 바이오컨쥬게이트
CN103497247A (zh) 2008-02-27 2014-01-08 诺沃—诺迪斯克有限公司 缀合的因子viii分子
KR101395431B1 (ko) * 2009-03-27 2014-05-14 아이제노에시쉐 테크니쉐 호히쉘 쮸리히 Ｃ. 제주니 ｎ-글리칸 또는 이의 유도체를 제시하는 살모넬라 엔테리카
DK2501406T3 (da) 2009-11-19 2018-02-26 Glaxosmithkline Biologicals Sa Biosyntese-system, der producerer immunogene polysaccharider i prokaryote celler
EP2545081B1 (en) 2010-02-11 2015-01-28 The Governors of the University of Alberta N-Linked Glycan Compounds
CA2798381C (en) * 2010-05-06 2020-10-06 Glycovaxyn Ag Capsular gram-positive bacteria bioconjugate vaccines
WO2012027850A1 (en) * 2010-09-03 2012-03-08 Christine Szymanski Peptide containing multiple n-linked glycosylation sequons
JP2014526449A (ja) * 2011-09-06 2014-10-06 グリコヴァキシン アーゲー 原核細胞において製造されるバイオコンジュゲートワクチン
EP3444352B1 (en) 2012-11-07 2020-12-16 GlaxoSmithKline Biologicals SA Production of recombinant vaccine in e. coli by enzymatic conjugation
TR201807924T4 (tr) 2013-01-17 2018-06-21 Arsanis Biosciences Gmbh MDR e. koli spesifik antikor.
WO2014111724A1 (en) 2013-01-18 2014-07-24 London School Of Hygiene And Tropical Medicine Glycosylation method
GB201301085D0 (en) 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
AU2014232722B2 (en) 2013-03-15 2017-03-09 Jiangsu Yahong Meditech Co., Ltd. Base addition salts of nitroxoline and uses thereof
ES2753369T3 (es) * 2013-04-05 2020-04-08 Univ Alberta Vacuna de Campylobacter
WO2015052344A1 (en) * 2013-10-11 2015-04-16 Glycovaxyn Ag Methods of host cell modification
EA035991B9 (ru) 2014-02-24 2020-10-21 Глаксосмитклайн Байолоджикалс С.А. Новый полисахарид и его применения
JP6682451B2 (ja) * 2014-04-17 2020-04-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変型宿主細胞およびその使用
EP3177325B1 (en) 2014-08-08 2020-04-01 GlaxoSmithKline Biologicals S.A. Modified host cells and hybrid oligosaccharides for use in bioconjugate production
BE1022998B1 (fr) * 2014-12-30 2016-10-28 Glycovaxyn Ag Compositions et procédés de glycosylation de protéines
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201518668D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Immunogenic Comosition
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
EP3573654A4 (en) * 2017-01-27 2020-11-25 University of Florida Research Foundation, Incorporated FOOD SAFETY VACCINE TO CONTROL SALMONELLA ENTERICA AND REDUCE CAMPYLOBACTER IN POULTRY
GB201712678D0 (en) 2017-08-07 2017-09-20 Glaxosmithkline Biologicals Sa Process for the manipulation of nucleic acids
US11898187B2 (en) 2017-08-15 2024-02-13 Northwestern University Protein glycosylation sites by rapid expression and characterization of N-glycosyltransferases
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
WO2019175145A1 (en) 2018-03-12 2019-09-19 Janssen Vaccines & Prevention B.V. Vaccines against urinary tract infections
US11530432B2 (en) 2018-03-19 2022-12-20 Northwestern University Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
WO2019204346A1 (en) 2018-04-16 2019-10-24 Northwestern University METHODS FOR CO-ACTIVATING IN VITRO NON-STANDARD AMINO ACID (nsAA) INCORPORATION AND GLYCOSYLATION IN CRUDE CELLLYSATES
WO2020072127A2 (en) 2018-08-03 2020-04-09 Northwestern University On demand, portable, cell-free molecular sensing platform
CN113227125A (zh) 2018-12-12 2021-08-06 葛兰素史密丝克莱恩生物有限公司 用于o-连接的糖基化的修饰的载体蛋白
AR118388A1 (es) * 2019-03-18 2021-09-29 Janssen Pharmaceuticals Inc Bioconjugados de antígenos-polisacáridos de e. coli, métodos de producción y métodos de utilización de los mismos
RS64521B1 (sr) 2019-03-18 2023-09-29 Janssen Pharmaceuticals Inc Postupci za proizvodnju biokonjugata polisaharida o-antigena e. coli, njihove kompozicije i postupci njihove primene
EP3757217A1 (en) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Methods for protein purification
EP3770269A1 (en) 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantification of bioconjugate glycosylation
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CN115038461A (zh) 2020-01-16 2022-09-09 杨森制药公司 FimH突变体、其组合物及其用途
US20230346902A1 (en) 2020-06-18 2023-11-02 Glaxosmithkline Biologicals Sa Shigella-Tetravalent (Shigella4V) Bioconjugate
JP2023531242A (ja) 2020-06-25 2023-07-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変Ｅｘｏｔｏｘｉｎ Ａタンパク質
IL301248B2 (en) 2020-09-17 2024-04-01 Janssen Pharmaceuticals Inc Multivalent vaccine compositions and their uses
WO2022153166A1 (en) 2021-01-12 2022-07-21 Janssen Pharmaceuticals, Inc. Fimh mutants, compositions therewith and use thereof
CN117222427A (zh) 2021-04-01 2023-12-12 杨森制药公司 大肠杆菌o18生物缀合物的生产
EP4452308A1 (en) 2021-12-22 2024-10-30 GlaxoSmithKline Biologicals S.A. Vaccine
GB202302579D0 (en) 2023-02-23 2023-04-12 Glaxosmithkline Biologicals Sa Immunogenic composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170204B1 (de) 1984-08-01 1991-09-25 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Neue genetische Sequenzen, die durch sie codierten Interferon-Peptide vom Typ I und diese sie produzierende Organismen
US5643758A (en) 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
EP0726318A1 (en) 1993-05-14 1996-08-14 The Upjohn Company An acceptor polypeptide for an N-acetylgalactosaminyltransferase
US6503744B1 (en) 1999-02-01 2003-01-07 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
CA2363297C (en) 1999-03-02 2011-08-09 Michael J. Betenbaugh Engineering intracellular sialylation pathways
US20020127219A1 (en) * 1999-12-30 2002-09-12 Okkels Jens Sigurd Lysosomal enzymes and lysosomal enzyme activators
EP1285072A2 (en) 2000-05-12 2003-02-26 Neose Technologies, Inc. In vitro fucosylation recombinant glycopeptides
AU7765801A (en) 2000-06-30 2002-01-08 Flanders Interuniversity Inst Protein glycosylation modification in pichia pastoris
DE10113573A1 (de) 2001-03-20 2002-02-28 Messer Griesheim Gmbh Verfahren zum Regenerieren von Schwefelsäure aus schwefelhaltigen Reststoffen
US20040265954A1 (en) 2002-03-07 2004-12-30 Markus Aebi System and method for the production of recombinant proteins
ES2258214T3 (es) 2002-03-07 2006-08-16 Eidgenossische Technische Hochschule Zurich Sistema y procedimiento para la produccion de proteinas glucosiladas recombinantes en un huesped procariotico.
JP4718174B2 (ja) * 2002-08-01 2011-07-06 ナショナル・リサーチ・カウンシル・オブ・カナダ カンピロバクターグリカンおよびグリコペプチド

Also Published As

Publication number Publication date
JP2014042533A (ja) 2014-03-13
IL226857A (en) 2017-08-31
KR20140019482A (ko) 2014-02-14
CN103396478A (zh) 2013-11-20
JP5827303B2 (ja) 2015-12-02
EP1888761A2 (en) 2008-02-20
JP5687637B2 (ja) 2015-03-18
JP2008539743A (ja) 2008-11-20
CN101360831B (zh) 2013-07-10
ES2535084T3 (es) 2015-05-05
WO2006119987A3 (en) 2007-03-08
US20100062484A1 (en) 2010-03-11
ES2703061T3 (es) 2019-03-06
EP1888761B1 (en) 2010-09-29
CN103396478B (zh) 2016-09-28
US8753864B2 (en) 2014-06-17
EP2311972B1 (en) 2015-01-21
HK1156983A1 (zh) 2016-11-25
PL2311972T3 (pl) 2015-08-31
US9551019B2 (en) 2017-01-24
EP2311972A1 (en) 2011-04-20
CA2607595C (en) 2018-11-27
EP2853600B1 (en) 2018-09-19
KR101524636B1 (ko) 2015-06-03
HK1113588A1 (en) 2008-10-10
IL187293A0 (en) 2008-04-13
SI2311972T1 (sl) 2015-08-31
CY1116285T1 (el) 2017-02-08
PT2311972E (pt) 2015-05-13
ATE483027T1 (de) 2010-10-15
AU2006245969B2 (en) 2011-06-02
DE602006017207D1 (de) 2010-11-11
HK1205193A1 (en) 2015-12-11
IL226857A0 (en) 2013-07-31
KR20080048990A (ko) 2008-06-03
PT1888761E (pt) 2011-01-03
IL187293A (en) 2013-06-27
AU2006245969B8 (en) 2011-08-25
DK2311972T3 (da) 2015-04-27
CN101360831A (zh) 2009-02-04
AU2006245969A1 (en) 2006-11-16
KR101408653B1 (ko) 2014-06-17
US20140323700A1 (en) 2014-10-30
CA2607595A1 (en) 2006-11-16
EP2853600A1 (en) 2015-04-01
ES2353814T3 (es) 2011-03-07
US20160326563A1 (en) 2016-11-10
JP2012100678A (ja) 2012-05-31
JP5356807B2 (ja) 2013-12-04
HRP20150312T1 (hr) 2015-07-31
WO2006119987A2 (en) 2006-11-16

Similar Documents

Publication Publication Date Title
DK1888761T3 (da) Rekombinante N-glycosylerede proteiner fra prokaryote celler
TNSN08064A1 (en) Albumin fusion proteins
BRPI0507623A (pt) peptìdeos da famìlia da amilina e métodos para prepará-los e empregá-los
WO2004099231A3 (en) Glycopegylation methods and proteins/peptides produced by the methods
MY169472A (en) Refolding of recombinant proteins
MX2010005783A (es) Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
PT1991680E (pt) Sistema para a expressão de componentes ortogonais de tradução em células hospedeiras eubacterianas
MX2009002816A (es) Proteinas de fusion de albumina.
DE602006019050D1 (de) Polypeptide mit cellobiohydrolaseaktivität und dafür kodierende polynukleotide
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
ATE512980T1 (de) Polypeptide mit beta-glucosidase-aktivität sowie diese codierende polynukleotide
WO2008121324A3 (en) Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
WO2007002261A3 (en) IL-1β BINDING ANTIBODIES AND FRAGMENTS THEREOF
MXPA03008715A (es) Reduccion de la inmunogenicidad de proteinas de fusion.
WO2002086144A3 (en) Compositions and methods for recombinational cloning of nucleic acid molecules
EA201100071A1 (ru) Новые композиции и способы
MX2008002485A (es) Polipeptidos que tienen actividad antimicrobiana y polinucleotidos que los codifican.
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof
WO2007045019A3 (en) Polyoleosins
TW200700076A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
WO2004039834A3 (en) Recombinant protein variants
TW200621284A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
AU2007258875A8 (en) Recombinant novirhabdoviruses and uses thereof
WO2003072733A3 (en) Modified bace
WO2007100384A3 (en) Three frame cdna expression libraries for functional screening of proteins